The oncology innovation landscape has become increasingly competitive, with capital, strategic attention, and acquisition interest concentrated around companies that can show clear differentiation early. For emerging oncology companies, scientific novelty alone is no longer enough. Investors and potential buyers are looking for focused strategies, credible development paths, and a clear view of where a company can create value in a crowded market.
J&J invites you to an event focused on how oncology startups can position themselves for investment, partnership, and potential acquisition in today’s market. The discussion will explore what different types of investors and acquirers are looking for, how expectations are evolving around patient selection and clinical trial design, and how companies can make strategic choices earlier in development that strengthen their future options.
The program will also examine how buyer expectations differ across the oncology ecosystem. While large pharma may continue to prioritize broader opportunities with substantial commercial potential, mid-sized pharma and other strategic buyers may be more attracted to focused mechanisms of action, niche indications, strong unmet need, and clear development logic. Understanding these differences can help founders avoid being boxed in too early and build a strategy that fits both the science and the market.
Join us in Utrecht or virtually for an open discussion with investors, pharma leaders, biotech executives, and advisors on what it takes to stand out in oncology today. The conversation will address changing market dynamics, competitive positioning, capital constraints, and the practical decisions that shape whether a company becomes investable, partnerable, or acquirable.
The program is tailored to oncology startups, academic innovators, investors, TTOs, incubators, and ecosystem partners interested in how promising oncology science can be translated into companies that are strategically focused, commercially credible, and attractive to future partners or buyers.
The program will bring together investors, pharma leaders, biotech executives and advisors to discuss how oncology startups can define a focused strategy, demonstrate differentiation, understand buyer expectations and make development choices that strengthen future opportunities.
This event is tailored to oncology startups, academic innovators, investors, technology transfer offices, incubators and ecosystem partners interested in helping promising oncologscience translate into successful companies.
📅 Tuesday 6 October
📍 Utrecht (NL) + virtual
